Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Glaukos Corporation (GKOS : NYSE)

• Company Description    Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Number of Employees: 995

• Price / Volume Information    Yesterday's Closing Price: $112.91 Daily Weekly Monthly 20 Day Moving Average: 599,983 shares Shares Outstanding: 57.44 (millions) Market Capitalization: $6,484.96 (millions) Beta: 0.67 52 Week High: $163.71 52 Week Low: $73.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.73% 3.91% 12 Week 29.75% 27.66% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 GLAUKOS WAY - ALISO VIEJO,CA 92656 USA ph: 949-367-9600 fax: 949-367-9984 investors@glaukos.com http://www.glaukos.com

• General Corporate Information    Officers Thomas W. Burns - Chief Executive Officer and Chairman Alex R. Thurman - Senior Vice President & Chief Financial Officer Mark J. Foley - Director David F. Hoffmeister - Director Marc A. Stapley - Director Peer Information Glaukos Corporation (ABMD) Glaukos Corporation (DMDS) Glaukos Corporation (CPWY.) Glaukos Corporation (EQUR) Glaukos Corporation (ECIA) Glaukos Corporation (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 377322102 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/19/26 Share - Related Items Shares Outstanding: 57.44 Most Recent Split Date: (:1) Beta: 0.67 Market Capitalization: $6,484.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.43 Price/Cash Flow: - Price / Sales: 13.80 EPS Growth vs. Year Ago Period: 42.86% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: 38.14% vs. Previous Quarter: 7.59% ROE 12/31/25 - - 09/30/25 - -7.52 06/30/25 - -8.59 ROA 12/31/25 - - 09/30/25 - -5.87 06/30/25 - -6.61 Current Ratio 12/31/25 - - 09/30/25 - 5.20 06/30/25 - 5.51 Quick Ratio 12/31/25 - - 09/30/25 - 4.47 06/30/25 - 4.69 Operating Margin 12/31/25 - - 09/30/25 - -12.27 06/30/25 - -14.70 Net Margin 12/31/25 - - 09/30/25 - -18.65 06/30/25 - -21.43 Pre-Tax Margin 12/31/25 - - 09/30/25 - -18.50 06/30/25 - -21.28 Book Value 12/31/25 - - 09/30/25 - 13.40 06/30/25 - 13.39 Inventory Turnover 12/31/25 - - 09/30/25 - 1.77 06/30/25 - 1.70 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.09 06/30/25 - 0.09 Debt-to-Capital 12/31/25 - - 09/30/25 - 8.17 06/30/25 - 8.25

Powered by Zacks Investment Research ©